PMC:3724972 / 26731-27610 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"With GR2 receptor blockade, ACTH and cortisol will likely increase, potentially resulting in hypokalemia, increased blood pressure, edema, or alkalosis through activation of mineralocorticoid receptors [75]. Other potential adverse reactions include adrenal insufficiency (AI) and endometrial thickening with vaginal bleeding—both requiring close monitoring and treatment [76, 77]. As there is no biochemical marker to follow (cortisol values are not reliable), treatment efficacy and potential adrenal insufficiency must be gauged through changes in clinical signs and symptoms [77]. Mifepristone is also a potent antagonist of progesterone, thus premenopausal women must be tested for pregnancy before administration. Caution is also warranted in combination with drugs metabolized by CYP3A or CYP2C (e.g., simvastatin, cyclosporine, fentanyl, ciprofloxacin, NSAIDs, warfarin).","tracks":[{"project":"2_test","denotations":[{"id":"23673515-15478032-63233676","span":{"begin":203,"end":205},"obj":"15478032"},{"id":"23673515-19289534-63233677","span":{"begin":373,"end":375},"obj":"19289534"},{"id":"23673515-22369976-63233678","span":{"begin":377,"end":379},"obj":"22369976"},{"id":"23673515-22369976-63233679","span":{"begin":580,"end":582},"obj":"22369976"}],"attributes":[{"subj":"23673515-15478032-63233676","pred":"source","obj":"2_test"},{"subj":"23673515-19289534-63233677","pred":"source","obj":"2_test"},{"subj":"23673515-22369976-63233678","pred":"source","obj":"2_test"},{"subj":"23673515-22369976-63233679","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#eca493","default":true}]}]}}